Three cell & gene therapy groups - ISCT, ARM & ASGCT - jointly call for 10-year global ban on human germline gene editing, ...

Omada, the virtual chronic care provider, joins virtual physical therapy company Hinge Health in testing the public market’s ...

The Trump administration laid out for the first time how Part B drugs could be selected for Medicare drug price negotiations ...

An order from a federal appeals court has kicked the battle wide open again over who holds the key patents for CRISPR-Cas9, a ...

A handful of generic and biosimilar manufacturers have said they feel prepared to ride out President Donald Trump’s potential ...

Galapagos is turning heads by reconsidering whether to do its planned spinoff, which was originally announced in January.

White House drug pricing plan faces skepticism as experts question feasibility of Trump's executive order to align US prices ...

To­day on Post Hoc Live, Drew Arm­strong is joined by Nick Ship­ley, the for­mer top lob­by­ist for the biotech in­dus­try, ...

Andrew Witty is out as CEO of UnitedHealth Group after a tumultuous couple of years that included the shooting death of a top ...

Plus, news about Neumora, Erasca, FibroGen, Tilt Biotherapeutics, Sangamo, Leap Therapeutics, Remedy Plan, Lexeo, Karyopharm, Tango Therapeutics and Humacyte.